Agilent Sees Opportunities in Toxicology as Paradigm, NIEHS Microarray Deal Extended | GenomeWeb

Agilent Technologies and Paradigm Genetics have extended an agreement on gene expression analysis equipment for toxicogenomics, the two companies announced last week.

Agilent will serve as sole provider for the equipment. Research Triangle Park, N.C.-based Paradigm will use Agilent’s 60-mer oligonucleotide-based microarrays, reagent chemistries, informatics, and instrumentation to produce data that will be collected in a public database managed by NIEHS’ National Center for Toxicogenomics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.